In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Previews, December 2013

Executive Summary

This Month's Profile Group, The Conundrum Of Alzheimer’s Disease R&D, features profiles of Alzheon, Neurotrack Technologies, Rodin Therapeutics, and Tetra Discovery Partners. Plus these Start-Ups Across Health Care: Footfalls & Heartbeats, GrayBug, HIL Applied Medical, and neoSurgical.

You may also be interested in...



Neurotrack Technologies Inc.

With Alzheimer’s researchers now looking to head off the disease in its earlier stages, the hunt is on for ways to detect its presence when patients aren’t necessarily showing symptoms. Neurotrack Technologies Inc. is building a noninvasive eye-tracking test that it believes could replace the ADAS-COG battery of neurological tests that are the current front line of diagnosis of the disease.

neoSurgical Inc.

Closing trocar site incisions during abdominal laparoscopic surgery can be challenging for surgeons, as the small incisions and limited visualization make it difficult to place sutures and securely close the abdominal wall. If not closed properly, a weakness can be created in the abdominal wall that can lead to herniation and other complications. neoSurgical Inc.’s neoClose is a device solution designed to properly and securely close the trocar wound with two suture/anchor assemblies.

HIL Applied Medical Ltd.

HIL Applied Medical Ltd. is developing a lighter and more compact particle accelerator for proton therapy that has the potential to dramatically change the way cancer patients are currently being treated. The start-up claims its technology will significantly reduce the cost of building and equipping a proton therapy center to the level where practically any community hospital can afford one.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel